Contribution of RNA-RNA Interactions Mediated by the Genome Packaging Signals for the Selective Genome Packaging of Influenza A Virus. 2022

Sho Miyamoto, and Yukiko Muramoto, and Keiko Shindo, and Yoko Fujita-Fujiharu, and Takeshi Morikawa, and Ryoma Tamura, and Jamie L Gilmore, and Masahiro Nakano, and Takeshi Noda
Laboratory of Ultrastructural Virology, Institute for Frontier Life and Medical Sciences, Kyoto Universitygrid.258799.8, Kyoto, Japan.

The influenza A virus genome is composed of eight single-stranded negative-sense viral RNA segments (vRNAs). The eight vRNAs are selectively packaged into each progeny virion. This process likely involves specific interactions between the vRNAs via segment-specific packaging signals located in both the 3'- and 5'-terminal regions of the respective vRNAs. To assess the importance of vRNA-vRNA interactions via packaging signals for selective genome packaging, we generated mutant viruses possessing silent mutations in the packaging signal region of the hemagglutinin (HA) vRNA. A mutant virus possessing silent mutations in nucleotides (nt) 1664 to 1676 resulted in defects in HA vRNA incorporation and showed a reduction in viral growth. After serial passage, the mutant virus acquired additional mutations in the 5'-terminal packaging signal regions of both the HA and polymerase basic 2 (PB2) vRNAs. These mutations contributed to the recovery of viral growth and HA vRNA packaging efficiency. In addition, an RNA-RNA interaction between the 5' ends of HA and PB2 vRNAs was confirmed in vitro, and this interaction was disrupted following the introduction of silent mutations in the HA vRNA. Thus, our results demonstrated that RNA-RNA interactions between the packaging signal regions of HA vRNA and PB2 vRNA are important for selective genome packaging. IMPORTANCE While numerous viral genomes comprise a single genome segment, the influenza A virus possesses eight segmented genomes. Influenza A virus can benefit from having a segmented genome because the segments can reassort with other strains of the influenza virus to create new genetically distinct strains. The influenza A virus efficiently incorporates one copy of each of its eight genomic segments per viral particle. However, the mechanism by which each segment is specifically selected is poorly understood. The genome segments contain RNA signals that facilitate the incorporation of segments into virus particles. These regions may facilitate specific interactions between the genome segments, creating an eight-segment complex, which can then be packaged into individual particles. In this study, we provide evidence that RNA signals contribute to specific interactions between two of the influenza virus genome segments.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009980 Influenza A virus The type species of the genus ALPHAINFLUENZAVIRUS that causes influenza and other diseases in humans and animals. Antigenic variation occurs frequently between strains, allowing classification into subtypes and variants. Transmission is usually by aerosol (human and most non-aquatic hosts) or waterborne (ducks). Infected birds shed the virus in their saliva, nasal secretions, and feces. Alphainfluenzavirus influenzae,Avian Orthomyxovirus Type A,FLUAV,Fowl Plague Virus,Human Influenza A Virus,Influenza Virus Type A,Influenza Viruses Type A,Myxovirus influenzae-A hominis,Myxovirus influenzae-A suis,Myxovirus pestis galli,Orthomyxovirus Type A,Orthomyxovirus Type A, Avian,Orthomyxovirus Type A, Human,Orthomyxovirus Type A, Porcine,Pestis galli Myxovirus,Fowl Plague Viruses,Influenza A viruses,Myxovirus influenzae A hominis,Myxovirus influenzae A suis,Myxovirus, Pestis galli,Myxoviruses, Pestis galli,Pestis galli Myxoviruses,Plague Virus, Fowl,Virus, Fowl Plague
D006388 Hemagglutinins Agents that cause agglutination of red blood cells. They include antibodies, blood group antigens, lectins, autoimmune factors, bacterial, viral, or parasitic blood agglutinins, etc. Isohemagglutinins,Exohemagglutinins,Hemagglutinin
D000086482 Viral Genome Packaging Folding of the viral genomic nucleic acid into the VIRUS PARTICLE. Packaging, Viral,Viral Packaging,Virus Genome Packaging,Packaging, Virus,Genome Packaging, Viral,Genome Packaging, Virus,Genome Packagings, Virus,Packaging, Virus Genome,Packagings, Virus,Packagings, Virus Genome,Virus Genome Packagings,Virus Packaging
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D014771 Virion The infective system of a virus, composed of the viral genome, a protein core, and a protein coat called a capsid, which may be naked or enclosed in a lipoprotein envelope called the peplos. Virus Particle,Viral Particle,Viral Particles,Particle, Viral,Particle, Virus,Particles, Viral,Particles, Virus,Virions,Virus Particles
D016679 Genome, Viral The complete genetic complement contained in a DNA or RNA molecule in a virus. Viral Genome,Genomes, Viral,Viral Genomes
D019065 Virus Assembly The assembly of VIRAL STRUCTURAL PROTEINS and nucleic acid (VIRAL DNA or VIRAL RNA) to form a VIRUS PARTICLE. Viral Assembly,Assembly, Viral,Assembly, Virus

Related Publications

Sho Miyamoto, and Yukiko Muramoto, and Keiko Shindo, and Yoko Fujita-Fujiharu, and Takeshi Morikawa, and Ryoma Tamura, and Jamie L Gilmore, and Masahiro Nakano, and Takeshi Noda
January 2007, Nucleic acids research,
Sho Miyamoto, and Yukiko Muramoto, and Keiko Shindo, and Yoko Fujita-Fujiharu, and Takeshi Morikawa, and Ryoma Tamura, and Jamie L Gilmore, and Masahiro Nakano, and Takeshi Noda
February 2019, Journal of virology,
Sho Miyamoto, and Yukiko Muramoto, and Keiko Shindo, and Yoko Fujita-Fujiharu, and Takeshi Morikawa, and Ryoma Tamura, and Jamie L Gilmore, and Masahiro Nakano, and Takeshi Noda
September 2006, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme,
Sho Miyamoto, and Yukiko Muramoto, and Keiko Shindo, and Yoko Fujita-Fujiharu, and Takeshi Morikawa, and Ryoma Tamura, and Jamie L Gilmore, and Masahiro Nakano, and Takeshi Noda
August 2020, Nature communications,
Sho Miyamoto, and Yukiko Muramoto, and Keiko Shindo, and Yoko Fujita-Fujiharu, and Takeshi Morikawa, and Ryoma Tamura, and Jamie L Gilmore, and Masahiro Nakano, and Takeshi Noda
February 2010, The Journal of general virology,
Sho Miyamoto, and Yukiko Muramoto, and Keiko Shindo, and Yoko Fujita-Fujiharu, and Takeshi Morikawa, and Ryoma Tamura, and Jamie L Gilmore, and Masahiro Nakano, and Takeshi Noda
October 2023, Journal of virology,
Sho Miyamoto, and Yukiko Muramoto, and Keiko Shindo, and Yoko Fujita-Fujiharu, and Takeshi Morikawa, and Ryoma Tamura, and Jamie L Gilmore, and Masahiro Nakano, and Takeshi Noda
October 2019, Journal of molecular biology,
Sho Miyamoto, and Yukiko Muramoto, and Keiko Shindo, and Yoko Fujita-Fujiharu, and Takeshi Morikawa, and Ryoma Tamura, and Jamie L Gilmore, and Masahiro Nakano, and Takeshi Noda
July 2021, Cold Spring Harbor perspectives in medicine,
Sho Miyamoto, and Yukiko Muramoto, and Keiko Shindo, and Yoko Fujita-Fujiharu, and Takeshi Morikawa, and Ryoma Tamura, and Jamie L Gilmore, and Masahiro Nakano, and Takeshi Noda
January 2015, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
Sho Miyamoto, and Yukiko Muramoto, and Keiko Shindo, and Yoko Fujita-Fujiharu, and Takeshi Morikawa, and Ryoma Tamura, and Jamie L Gilmore, and Masahiro Nakano, and Takeshi Noda
July 2020, Journal of virology,
Copied contents to your clipboard!